These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38426768)

  • 1. Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase.
    Gao Y; Wang M; Liu X
    Microbiol Spectr; 2024 Apr; 12(4):e0394123. PubMed ID: 38426768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.
    Duan M; Chi X; Xiao H; Liu X; Zhuang H
    Hepatol Int; 2021 Apr; 15(2):318-327. PubMed ID: 33638049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for significant histological changes in both HBeAg positive and negative treatment-naive chronic hepatitis B with persistently normal alanine aminotransferase level.
    Xu C; Zhao Y; Chen H; Ren W; Yang X; Zheng W; Yin Q; Pan H
    BMC Infect Dis; 2024 Oct; 24(1):1120. PubMed ID: 39379873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
    Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
    World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT.
    Duan M; Xiao H; Shi M; Xie Y; Zhao P; Li S; Chi X; Liu X; Zhuang H
    BMC Infect Dis; 2024 Jul; 24(1):723. PubMed ID: 39044129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total serum bile acids predict therapy for HBeAg-negative chronic hepatitis B patients with borderline ALT and high HBV DNA.
    Xie R; Li J; Zhang H; Wang LM; Huang CR; Chen LW
    J Infect Dev Ctries; 2022 Aug; 16(8):1336-1342. PubMed ID: 36099378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B.
    Jiang C; Liu J; Li R; Chen K; Peng W; Fu L; Peng S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):698-706. PubMed ID: 37539572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone.
    Ren S; Wang W; Lu J; Wang K; Ma L; Zheng Y; Zheng S; Chen X
    Front Immunol; 2022; 13():1035923. PubMed ID: 36389814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with chronic hepatitis B who have persistently normal alanine aminotransferase or aged < 30 years may exhibit significant histologic damage.
    Wei S; Xie Q; Liao G; Chen H; Hu M; Lin X; Li H; Peng J
    BMC Gastroenterol; 2024 Mar; 24(1):120. PubMed ID: 38532310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT.
    Wu Z; Ma AL; Xie Q; Zhang XQ; Cheng J; Zhang DZ; Wang GQ; Zhao H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101463. PubMed ID: 32571749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B.
    Xie Q; Hu X; Zhang Y; Jiang X; Li X; Li J
    J Med Virol; 2014 Nov; 86(11):1828-37. PubMed ID: 25145769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels.
    Xie Y; Yi W; Zhang L; Lu Y; Hao HX; Gao YJ; Ran CP; Lu HH; Chen QQ; Shen G; Wu SL; Chang M; Ping-Hu L; Liu RY; Sun L; Wan G; Li MH
    J Viral Hepat; 2019 Jul; 26 Suppl 1():42-49. PubMed ID: 31380591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
    Yan JY; Li ZQ; Yu ZJ; Kan QC
    J Cell Biochem; 2019 Apr; 120(4):6632-6641. PubMed ID: 30368885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China.
    Xing YF; Zhou DQ; He JS; Wei CS; Zhong WC; Han ZY; Peng DT; Shao MM; Sham TT; Mok DK; Chan CO; Tong GD
    PLoS One; 2018; 13(9):e0203220. PubMed ID: 30180183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.